title: Reply: Platelet reactivity is preferred over genotyping in monitoring efficacy of antiplatelet therapy.
authors.forename: Chiara Viviani
authors.initials: CV
authors.lastname: Anselmi
authors.forename: Carlo
authors.initials: C
authors.lastname: Briguori
authors.forename: Roberta
authors.initials: R
authors.lastname: Roncarati
authors.forename: Laura
authors.initials: L
authors.lastname: Papa
authors.forename: Gabriella
authors.initials: G
authors.lastname: Visconti
authors.forename: Amelia
authors.initials: A
authors.lastname: Focaccio
authors.forename: Francesca
authors.initials: F
authors.lastname: De Micco
authors.forename: Michael V G
authors.initials: MV
authors.lastname: Latronico
authors.forename: Paolo
authors.initials: P
authors.lastname: Pagnotta
authors.forename: Gianluigi
authors.initials: G
authors.lastname: Condorelli
mesh_terms: D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D003324:Coronary Artery Disease / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation*; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011110:Polymorphism, Genetic; D013988:Ticlopidine / Q000031:analogs & derivatives*
chemical_list: D010975:Platelet Aggregation Inhibitors; D001189:Aryl Hydrocarbon Hydroxylases; D013988:Ticlopidine